The International Prognostic Index for patients with chronic lymphocytic leukemia
The CLL-IPI allows more individualized management of CLL patients in clinical practice (cf. The International CLL-IPI working group; The Lancet Oncology 2016).
This risk score separates four risk groups with significantly different OS at five years: low (93.2%), intermediate (79.3%), high (63.3%), and very high risk (23.3%).
It was developed using the individual patient data of eight phase-III clinical trials from France, Germany, UK, USA and Poland comprising 3472 treatment-naive patients and validated in multiple independent cohorts of CLL patients from Mayo Clinic and Sweden. The proposal and validation was conducted by the International CLL-IPI working group. Results of the index should be used for risk-stratification and patient counseling but should not be used as a way to determine the need for treatment which should be based on the iWCLL criteria (Blood 111:5446). Estimates of survival were based on assessment of patients treated prior to the current era of targeted signaling inhibitors. Therefore, these predictions should be applied with caution to individual patients and are meant to help in decision making.
International CLL-IPI working group.
da Cunha-Bang C, Christiansen I, Niemann CU.
Gentile M, Shanafelt TD, Rossi D, et al.
Molica S, Shanafelt TD, Giannarelli D, et al.
The CLL-IPI allows more individualized management of CLL patients in clinical practice (cf. The International CLL-IPI working group; The Lancet Oncology 2016).
This risk score separates four risk groups with significantly different OS at five years: low (93.2%), intermediate (79.3%), high (63.3%), and very high risk (23.3%).
It was developed using the individual patient data of eight phase-III clinical trials from France, Germany, UK, USA and Poland comprising 3472 treatment-naive patients and validated in multiple independent cohorts of CLL patients from Mayo Clinic and Sweden. The proposal and validation was conducted by the International CLL-IPI working group. Results of the index should be used for risk-stratification and patient counseling but should not be used as a way to determine the need for treatment which should be based on the iWCLL criteria (Blood 111:5446). Estimates of survival were based on assessment of patients treated prior to the current era of targeted signaling inhibitors. Therefore, these predictions should be applied with caution to individual patients and are meant to help in decision making.
International CLL-IPI working group.
da Cunha-Bang C, Christiansen I, Niemann CU.
Gentile M, Shanafelt TD, Rossi D, et al.
Molica S, Shanafelt TD, Giannarelli D, et al.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
